Aclaris Therapeutics Inc. [NASDAQ: ACRS] surged by $0.08 during the normal trading session on Thursday and reaching a high of $8.39 during the day while it closed the day at $8.33. The company report on March 27, 2023 that Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Aclaris Therapeutics Inc. stock has also gained 2.21% of its value over the past 7 days. However, ACRS stock has declined by -46.22% in the 3 months of the year. Over the past six months meanwhile, it has lost -43.22% and lost -47.11% year-on date.
The market cap for ACRS stock reached $565.19 million, with 66.70 million shares outstanding and 60.26 million shares in the current float. Compared to the average trading volume of 1.05M shares, ACRS reached a trading volume of 3938543 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Aclaris Therapeutics Inc. [ACRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACRS shares is $29.12 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACRS stock is a recommendation set at 1.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stifel have made an estimate for Aclaris Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 14, 2022. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on December 01, 2022, representing the official price target for Aclaris Therapeutics Inc. stock. Previously, the target price had yet another raise to $32, while BTIG Research analysts kept a Buy rating on ACRS stock. On July 23, 2021, analysts increased their price target for ACRS shares from 27 to 32.
The Average True Range (ATR) for Aclaris Therapeutics Inc. is set at 0.65, with the Price to Sales ratio for ACRS stock in the period of the last 12 months amounting to 18.97. The Price to Book ratio for the last quarter was 2.81, with the Price to Cash per share for the same quarter was set at 3.21.
ACRS stock trade performance evaluation
Aclaris Therapeutics Inc. [ACRS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.21. With this latest performance, ACRS shares dropped by -31.94% in over the last four-week period, additionally sinking by -43.22% over the last 6 months – not to mention a drop of -53.33% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACRS stock in for the last two-week period is set at 37.26, with the RSI for the last a single of trading hit 43.37, and the three-weeks RSI is set at 35.60 for Aclaris Therapeutics Inc. [ACRS]. The present Moving Average for the last 50 days of trading for this stock 11.92, while it was recorded at 8.15 for the last single week of trading, and 14.89 for the last 200 days.
Aclaris Therapeutics Inc. [ACRS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Aclaris Therapeutics Inc. [ACRS] shares currently have an operating margin of -286.21 and a Gross Margin at +59.80. Aclaris Therapeutics Inc.’s Net Margin is presently recorded at -292.11.
Return on Total Capital for ACRS is now -42.57, given the latest momentum, and Return on Invested Capital for the company is -43.59. Return on Equity for this stock declined to -44.01, with Return on Assets sitting at -34.14. When it comes to the capital structure of this company, Aclaris Therapeutics Inc. [ACRS] has a Total Debt to Total Equity ratio set at 1.14. Additionally, ACRS Total Debt to Total Capital is recorded at 1.13, with Total Debt to Total Assets ending up at 0.87. Long-Term Debt to Equity for the company is recorded at 0.79, with the Long-Term Debt to Total Capital now at 0.79.
Reflecting on the efficiency of the workforce at the company, Aclaris Therapeutics Inc. [ACRS] managed to generate an average of -$827,695 per employee. Receivables Turnover for the company is 53.75 with a Total Asset Turnover recorded at a value of 0.12.Aclaris Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 10.60 and a Current Ratio set at 10.60.
Aclaris Therapeutics Inc. [ACRS]: Insider Ownership positions
There are presently around $545 million, or 96.50% of ACRS stock, in the hands of institutional investors. The top three institutional holders of ACRS stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 5,484,013, which is approximately 58.78% of the company’s market cap and around 0.20% of the total institutional ownership; BLACKROCK INC., holding 5,088,659 shares of the stock with an approximate value of $41.98 million in ACRS stocks shares; and VR ADVISER, LLC, currently with $37.65 million in ACRS stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Aclaris Therapeutics Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 63 institutional holders increased their position in Aclaris Therapeutics Inc. [NASDAQ:ACRS] by around 5,882,610 shares. Additionally, 50 investors decreased positions by around 3,908,157 shares, while 33 investors held positions by with 56,228,542 shares. The mentioned changes placed institutional holdings at 66,019,309 shares, according to the latest SEC report filing. ACRS stock had 16 new institutional investments in for a total of 2,667,553 shares, while 13 institutional investors sold positions of 713,398 shares during the same period.